Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Research & Development (2016 - 2025)

Lipocine's Research & Development history spans 13 years, with the latest figure at $2.1 million for Q3 2025.

  • For Q3 2025, Research & Development rose 32.47% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $5.7 million, up 112.24%, while the annual FY2024 figure was $4.1 million, 38.81% down from the prior year.
  • Research & Development reached $2.1 million in Q3 2025 per LPCN's latest filing, down from $3.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.7 million in Q3 2023 to a low of -$1.8 million in Q4 2023.
  • Average Research & Development over 5 years is $1.7 million, with a median of $1.6 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 420.1% in 2021, then tumbled 170.37% in 2023.
  • A 5-year view of Research & Development shows it stood at $1.5 million in 2021, then surged by 70.56% to $2.6 million in 2022, then crashed by 170.37% to -$1.8 million in 2023, then soared by 122.22% to $400000.0 in 2024, then skyrocketed by 425.0% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Research & Development are $2.1 million (Q3 2025), $3.1 million (Q2 2025), and $109000.0 (Q1 2025).